Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Biomarker clustering in autosomal dominant Alzheimer's disease
Luckett, Patrick H. , Chen, Charlie, Gordon, Brian A. , Wisch, Julie K. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Wang, Qing , Marcus, Daniel C. , Koudelis, Deborah, Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Wisch, Julie K , Berman, Sarah , Noble, James M , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Marcus, Daniel, Joseph‐Mathurin, Nelly , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | April 1, 2022 | Volume: 19 | Issue: 1 | Pages: 274-284

10.1002/alz.12661 | PMID 35362200 Get It

AbstractINTRODUCTIONAs the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others.METHODSWe used hierarchical clustering to group 19 cross‐sectional biomarkers in autosomal dominant AD. Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO). Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.RESULTSThree primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers. Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO. Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.DISCUSSIONThese results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.
Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors
Koubek, Emily J. , Ralya, Andrew T., Larson, Thomas R. , McGovern, Renee M., Buhrow, Sarah A. , Covey, Joseph M. , Adjei, Alex A. , Takebe, Naoko , Ames, Matthew M. , Reid, Joel M. , Goetz, Matthew P.

Mayo Clinic

The Journal of Clinical Pharmacology | March 31, 2022 | Volume: 62 | Issue: 9 | Pages: 1121-1131

10.1002/jcph.2053 | PMID 35358345 Get It

AbstractThe purpose of this study was to develop and validate a population pharmacokinetic model for Z‐endoxifen in patients with advanced solid tumors and to identify clinical variables that influence pharmacokinetic parameters. Z‐endoxifen‐HCl was administered orally once a day on a 28‐day cycle (±3 days) over 11 dose levels ranging from 20 to 360 mg. A total of 1256 Z‐endoxifen plasma concentration samples from 80 patients were analyzed using nonlinear mixed‐effects modeling to develop a population pharmacokinetic model for Z‐endoxifen. A 2‐compartment model with oral depot and linear elimination adequately described the data. The estimated apparent total clearance, apparent central volume of distribution, and apparent peripheral volume of distribution were 4.89 L/h, 323 L, and 39.7 L, respectively, with weight‐effect exponents of 0.75, 1, and 1, respectively. This model was used to explore the effects of clinical and demographic variables on Z‐endoxifen pharmacokinetics. Weight, race on clearance, and aspartate aminotransferase on the absorption rate constant were identified as significant covariates in the final model. This novel population pharmacokinetic model provides insight regarding factors that may affect the pharmacokinetics of Z‐endoxifen and may assist in the design of future clinical trials.
CLO22-067: Symptom Burden in Patients With Myelofibrosis who Have Moderate or Severe Thrombocytopenia: A Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study
Palmer, Jeanne , Rampal, Raajit K. , Buckley, Sarah , Roman‐Torres, Karisse, Mesa, Ruben A. , Bose, Prithviraj , Oh, Stephen T. , Verstovšek, Srđan , Mascarenhas, John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: CLO22-067

10.6004/jnccn.2021.7287 Get It

In It for the Long Haul: Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2
Gosser, Rena , Anderson, Sarah , Jen, Christi, Bhatt, Snehal H., Anderson, Sarah, Blaszczyk, Amie Taggart

Mayo Clinic

Journal of Pharmacy Practice | March 31, 2022 | Volume: 36 | Issue: 5 | Pages: 1048-1051

10.1177/08971900221088799 | PMID 35356830 Get It

The COVID-19 pandemic has caused immeasurable clinical, economic, and societal challenges for the world since early 2020. Intense focus has been placed on determining evidence-based acute management of patients infected with the SARS-CoV-2 virus, as well as accelerating vaccination efforts for those eligible to receive it. As patients recover from infection, many are left with long-term symptoms, known as “Long COVID” or “Post-Acute Sequelae of COVID19,” that challenges the ability to fully recover, return to baseline health status, and regain quality of life. As the most accessible healthcare professional, pharmacists can assist with the management of long COVID as a member of the multidisciplinary team. Pharmacists' medication acumen is beneficial to the management of long COVID symptomatology as more research comes to the forefront of this deadly disease.
Dermatofibrosarcoma Protuberans Recurrence After Wide Local Excision Versus Mohs Micrographic Surgery: A Systematic Review and Meta-Analysis
Martin, Emma C. St., Vyas, Krishna S., Batbold, Sarah, Erwin, Patricia J., Brewer, Jerry D., Vyas, Krishna S. , Martin, Emma C. St., Vyas, Krishna S., Batbold, Sarah, Erwin, Patricia J., Brewer, Jerry D.

Mayo Clinic

Dermatologic Surgery | March 30, 2022 | Volume: 48 | Issue: 5 | Pages: 479-485

10.1097/dss.0000000000003411 | PMID 35353755 Get It

BACKGROUND Local recurrence (LR) rates of dermatofibrosarcoma protuberans (DFSP) treated with different surgical modalities are unknown. OBJECTIVE To evaluate the differences in LR rates of DFSP treated with wide local excision (WLE) versus Mohs micrographic surgery (MMS). MATERIALS AND METHODS Pertinent studies of DFSP treated with either WLE or MMS were identified through a search of multiple databases, including Ovid MEDLINE (1946–2018), Embase (1988–2018), Web of Science (1975–2018), and Scopus (1970–2018). Comparative 2-arm and noncomparative single-arm studies were assessed through meta-analyses. RESULTS Of the 517 studies identified, 88 met inclusion criteria (12 comparative studies; 76 single-arm studies). In the 12 comparative studies, 352 patients with DFSP underwent MMS and 777 patients with DFSP underwent WLE. The LR rate was 1.7% after MMS and 3.7% after WLE (odds ratio, 1.549; 95% CI, 0.710–3.381; p = .27). In the 76 noncomparative studies, 980 patients underwent MMS (LR rate, 1.5%; 95% CI, 0.9%–2.1%; p < .001), and 2,215 patients underwent WLE (LR rate, 9.4%; 95% CI, 7.5%–11.3%; p < .001). CONCLUSION The LR rate of DFSP in patients treated with MMS is lower than in patients treated with WLE. Because of high rates of postoperative DFSP LR, MMS should be strongly considered when available.
Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States
Li, Dingfeng , Hamidi, Oksana , Westfall, Ashleigh A, Suresh, Malavika, Else, Tobias , Vaidya, Anand , Hamidi, Oksana , Else, Tobias , Bancos, Irina , Brand, Sarah, Westfall, Ashleigh, Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 29, 2022 | Volume: 107 | Issue: 7 | Pages: e2851-e2861

10.1210/clinem/dgac175 | PMID 35350067 Get It

Abstract Context Current evidence on determinants of quality of life (QoL) in patients with adrenal insufficiency (AI) is limited. Objective This work aimed to identify the determinants of QoL in different subtypes of AI. Methods This multicenter cross-sectional survey study was conducted using a patient-centered questionnaire, the Short Form-36. Results Of 529 participants, 223 (42.2%) had primary AI, 190 (35.9%) had secondary AI, and 116 (21.9%) had glucocorticoid-induced AI. Median age was 58 years (interquartile range: 43-68 years) and 342 (64.8%) were women. In multivariable analyses, patients were more likely to report worse physical scores if they were women (odds ratio [OR]: 3.3; 95% CI, 1.8-6.0), had secondary AI or glucocorticoid-induced AI (OR: 2.5; 95% CI, 1.4-4.3), had shorter duration of AI (OR: 2.0; 95% CI, 1.1-3.6), were treated with more than 25 mg hydrocortisone equivalent daily (OR: 2.3; 95% CI, 1.2-4.6), had more comorbidities related to glucocorticoid excess (OR: 2.3; 95% CI, 1.3-4.0), reported a higher financial burden from AI (OR: 2.1; 95% CI, 1.3-3.6), and reported difficulties with AI management (OR: 2.5; 95% CI, 1.2-5.2). Women (OR: 2.1; 95% CI, 1.08-4.0), shorter duration of AI (OR: 2.4; 95% CI, 1.4-4.3), higher financial burden (OR: 2.3; 95% CI, 1.3-4.0), difficulties with AI management (OR: 2.6; 95% CI, 1.4-4.9), and lack of family support (OR: 9.1; 95% CI, 2.3-33.3) were associated with worse mental component scores. Conclusion In patients with AI, QoL could be improved by addressing certain determinants, such as avoiding GC overreplacement, providing in-depth education on self-management, offering more comprehensive insurance coverage, and ensuring better family support.
Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor–Positive Breast Cancer
Abubakar, Mustapha , Mullooly, Maeve , Nyante, Sarah J. , Pfeiffer, Ruth M. , Bowles, Erin J. Aiello , Cora, Renata , Bodelón, Clara , Butler, Eboneé N. , Butcher, Donna , Sternberg, Lawrence, Weinmann, Sheila , Glass, Andrew G., González, Amy Berrington de , Gierach, Gretchen L. , Nyante, Sarah , Aiello Bowles, Erin J , Butler, Eboneé , Sherman, Mark , Berrington de Gonzalez, Amy , Gierach, Gretchen L , Pfeiffer, Ruth M , Troester, Melissa A. , Sherman, Mark E.

Mayo Clinic

JNCI Cancer Spectrum | March 29, 2022 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/jncics/pkac028 | PMID 35583138 Get It

Abstract Background Mammographic breast density (MBD) decline post-tamoxifen initiation is a favorable prognostic factor in estrogen receptor (ER)–positive breast cancer (BC) and has potential utility as a biomarker of tamoxifen response. However, the prognostic value of MBD decline may vary by molecular characteristics among ER–positive patients. Methods We investigated associations between MBD decline (≥10% vs &lt;10%) and breast cancer–specific mortality (BCSM) among ER–positive breast cancer patients aged 36-87 years at diagnosis treated with tamoxifen at Kaiser Permanente Northwest (1990-2008). Patients who died of BC (case patients; n = 62) were compared with those who did not (control patients; n = 215) overall and by tumor molecular characteristics (immunohistochemistry [IHC]–based subtype [luminal A–like: ER–positive/progesterone receptor [PR]–positive/HER2–negative/low Ki67; luminal B–like: ER–positive and 1 or more of PR–negative, HER2–positive, high Ki67] and modified IHC [mIHC]–based recurrence score of ER/PR/Ki67). Percent MBD was measured in the unaffected breast at baseline mammogram (mean = 6 months before tamoxifen initiation) and follow-up (mean = 12 months post-tamoxifen initiation). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed from logistic regression models. All statistical tests were 2-sided. Results MBD decline was statistically significantly associated with reduced risk of BCSM overall (OR = 0.38, 95% CI = 0.15 to 0.92). This association was, however, stronger among women with aggressive tumor characteristics including luminal B–like (OR = 0.17, 95% CI = 0.04 to 0.73) vs A–like (OR = 0.74, 95% CI = 0.19 to 2.92); large (OR = 0.26, 95% CI = 0.08 to 0.78) vs small (OR = 0.41, 95% CI = 0.04 to 3.79) tumors; PR–negative (OR = 0.02, 95% CI = 0.001 to 0.37) vs PR–positive (OR = 0.50, 95% CI = 0.18 to 1.40) disease; and high (OR = 0.25, 95% CI = 0.07 to 0.93) vs low (OR = 0.44, 95% CI = 0.10 to 2.09) mIHC3 score. Conclusion The findings support MBD decline as a prognostic marker of tamoxifen response among patients with aggressive ER–positive BC phenotypes, for whom understanding treatment effectiveness is critical.
Rapid Deployment of Team Nursing During a Pandemic: Implementation Strategies and Lessons Learned
Johnson, Maren, Lehnertz, Andrea Y., Kramer, Robert R., Drilling, Kelly E., Bungum, Lisa D., Bell, Sarah, Johnson, Maren R, Bell, Sarah J. , Jones, Kelly L., Lehnertz, Andrea Y., Bungum, Lisa D.

Mayo Clinic

Critical Care Nurse | March 24, 2022 | Volume: 42 | Issue: 3 | Pages: 27-36

10.4037/ccn2022399 | PMID 35322267 Get It

Background The COVID-19 pandemic increased the number of patients requiring intensive care nation-wide, leading to nurse staffing shortages in many units. Local Problem At the beginning of the statewide COVID-19 surge, a tertiary teaching hospital in the upper Midwest experienced a sharp increase in patients needing intensive care. To relieve the resulting staffing shortage, it implemented a pilot program to bring general care nurses into its 21-bed mixed specialty intensive care unit to free intensive care unit nurses to help staff the hospital’s COVID-designated units. Methods Using a team nursing model, the intensive care unit recruited, oriented, and incorporated 13 general care nurses within 4 days. Education and resources were developed to distinguish team nurses from intensive care unit nurses, introduce them to the intensive care unit environment, outline expectations, communicate between team nursing pairs, and guide charge nurses in making staffing decisions and assignments. Staff feedback identified additional resources, barriers, and successes. An adaptive process was used to improve and update tools and resources on the basis of staff needs. Results The pilot program ran for 6 weeks. Positive outcomes included a reduced need for float nurses and self-perceived reduction in nursing workload. The principal barrier was charge nurses’ challenges involving staffing-to-workload balance based on the existing staffing model. This model identified productivity of a general care nurse and an intensive care unit nurse as equivalent, despite differences in their skill sets. Conclusion Team nursing in the intensive care unit is an agile tactic easily replicated in dire staffing situations.
Late Complications of COVID-19
Roden, Anja C. , Johnson, Tucker F. , Aubry, Marie Christine, Butt, Yasmeen M. , Maleszewski, Joseph J. , Larsen, Brandon T. , Tazelaar, Henry D. , Khoór, András , Moua, Teng , Jenkins, Sarah M. , Moyer, Ann M. , Yi, Eunhee , Bois, Melanie C. , Boland, Jennifer M. , Lo, Ying‐Chun , Tazelaar, Henry D. , Smith, Maxwell L. , Yi, Eunhee S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 23, 2022 | Volume: 146 | Issue: 7 | Pages: 791-804

10.5858/arpa.2021-0519-sa | PMID 35319744 Get It

Context.— Studies of lungs in patients with COVID-19 have focused on early findings. Objective.— To systematically study histopathologic and imaging features and presence of SARS-CoV-2 RNA in lung tissue from patients in later stages of COVID-19. Design.— Autopsies, explants, surgical lung biopsies, transbronchial biopsies, cryobiopsies, and needle biopsies from patients with COVID-19 whose onset of symptoms/confirmed diagnosis was more than 28 days before the procedure were studied. Available images were reviewed. Reverse transcription droplet digital polymerase chain reaction for SARS-CoV-2 RNA was performed on lung tissue. Results.— Of 44 specimens (43 patients; median age, 59.3 years; 26 [60.5%] male) features of acute lung injury (ALI) were seen in 39 (88.6%), predominantly organizing pneumonia and diffuse alveolar damage, up to 298 days after onset of COVID-19. Fibrotic changes were found in 33 specimens (75%), most commonly fibrotic diffuse alveolar damage (n = 22) and cicatricial organizing pneumonia (n = 12). Time between acquiring COVID-19 and specimen was shorter in patients with diffuse ALI (median, 61.5 days) compared with patients with focal (140 days) or no ALI (130 days) (P = .009). Sixteen (of 20; 80%) SARS-CoV-2 reverse transcription droplet digital polymerase chain reaction tests were positive, up to 174 days after COVID-19 onset. Time between COVID-19 onset and most recent computed tomography in patients with consolidation on imaging was shorter (median, 43.0 days) versus in patients without consolidation (87.5 days; P = .02). Reticulations were associated with longer time to computed tomography after COVID-19 onset (median, 82 versus 23.5 days; P = .006). Conclusions.— ALI and SARS-CoV-2 RNA can be detected in patients with COVID-19 for many months. ALI may evolve into fibrotic interstitial lung disease.
De Ritis‐adjusted AST provides comparable efficacy to lactate dehydrogenase as a biomarker for detection of LVAD hemolysis or thrombosis
Schettle, Sarah , Rosenbaum, Andrew , Goodman, Daniel , Stulak, John M.

Mayo Clinic

Artificial Organs | March 23, 2022 | Volume: 46 | Issue: 7 | Pages: 1425-1428

10.1111/aor.14236 | PMID 35318681 Get It

Abstract Background Lactate hydrogenase (LDH) is a common biomarker utilized in the detection and monitoring of left ventricular assist device (LVAD) hemolysis and thrombosis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are common laboratory tests that can be used to calculate the De Ritis ratio and the De Ritis adjusted AST. Methods A retrospective review of LVAD patients was performed to identify three cohorts of patients: those with confirmed pump thrombosis after device exchange, those with LVAD‐related hemolysis who were medically managed without pump exchange, and those who did not meet these criteria and served as the control cohort. Evaluation of AST, AST/ALT ratio (referred to as the De Ritis ratio) as well as AST x (AST/ALT) or the De Ritis‐adjusted AST (DRA) was performed. Results There were 29 patients who underwent device exchange for thrombosis, 25 patients who were diagnosed with hemolysis and treated medically (clopidogrel ( N = 6), heparin ( N = 13), tirofiban ( N = 8), eptifibatide ( N = 2), and some received more than one of these treatments), and 425 control patients. A qualitatively comparable relative and absolute rise in DRA and LDH were found in both surgically managed pump thrombosis and suspected device‐related hemolysis. Conclusions Both AST and LDH as well DRA are significantly associated with pump thrombosis ( p < 0.0001 for each). DRA is a potential screening biomarker for hemolysis and device thrombosis in stable left ventricular assist device patients.